ATTAIN: what the trials say vs what this community says
Thinking out loud about this: ATTAIN: what the trials say vs what this community says.
The analytical point, which this board keeps getting wrong by importing habits from the peptide side.
For a peptide, purity is typically reported as area percent by HPLC with identity by mass spectrometry, and the impurity classes are things like deletion and oxidation products. For a small molecule the relevant impurities are synthetic intermediates, degradants and residual solvents, and identity is established differently.
So the certificate you would want looks different, the questions to ask are different, and a "purity" figure quoted here is not comparable to one quoted on the peptide boards. Anybody posting a result should say what method produced it, which is good practice everywhere and essential here.
It is a non-peptide small-molecule agonist at the GLP-1 receptor. That is a substantial medicinal chemistry achievement: getting a small molecule to activate a receptor evolved for a peptide ligand.
Because it is not a peptide, it is not subject to the same degradation pathways, does not require the absorption enhancers used for oral peptides, and can be formulated as a conventional tablet.
Please do not ask me what dose you should be on. I genuinely do not know and neither does anyone else here.
best — the order this archive was captured in
Nothing containing this compound is approved by any regulator, and research-use-only material is not approved for human use.
daily dosing changes adherence in both directions
Spent an evening reading about small-molecule agonism at a peptide receptor. Genuinely interesting engineering.
small molecule, not a peptide, and that changes everything about it
Small fix — the two programme names got swapped upthread and it changes which population the figure came from.
Small fix — the two programme names got swapped upthread and it changes which population the figure came from.
Disagreeing with this bit: daily dosing is a different adherence problem, not a better one.
Agreed that phase 3 is where the comparison becomes fair. Everything before it is inference.
Read both programme names carefully after mixing them up in a comment and being politely corrected.
do not assume reconstitution intuitions apply, there is nothing to reconstitute
the boards keep comparing it to injectables at matched doses, which is meaningless
What is actually known, and what is being assumed.
Known: it is a small-molecule GLP-1 receptor agonist, dosed daily, with clinical programmes reporting in both obesity and type 2 diabetes. Its tolerability profile broadly resembles the class in the data published so far.
Assumed, frequently and confidently: that milligram comparisons with injectables mean something, that adherence is straightforwardly better because it is a tablet, that peptide purity discussions transfer to it. None of those hold. And nothing containing this compound is approved anywhere, which makes research-use-only material exactly that — not approved for human use.
ATTAIN and ACHIEVE are the programmes to keep straight